German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
“We are on the threshold of a new era of innovation in the life sciences.” commented Werner Baumann, Chairman of the Board at Bayer AG. The budget, which equals the amount of investments made by Leaps by Bayer of the past seven years, is earmarked for investments in medical and agri-biotech
Additionally, Bayer AG has invested €2.5bn to drive activities in gene and cell therapy through the acquisition of Blue Rock Therapeutics and Asklepios Biopharmaceutical (AskBio) as well as a partnership with US company Cellino Biotech, that invented the very first fully automated production platform for autologous cell therapies. Furthermore, there are billion-dollar collaborations with mostly US companies such as Mammoth Biosciences.